Key Points The world’s first mRNA lung cancer vaccine trial, named BNT116, has begun in seven countries. Developed by BioNTech, the vaccine targets non-small cell lung cancer (NSCLC), the most common type of lung cancer. The trial includes 34 research sites, with six based in the UK, and involves approximately 130 patients. The vaccine uses mRNA technology similar to that of COVID-19 vaccines, aiming to train the immune system to attack cancer cells while sparing healthy ones. Current lung cancer treatments have…